Skip to content

    Multiple Sclerosis Health Center

    Font Size

    Asthma Drug Albuterol May Help Treat MS

    Study Shows Albuterol Has Potential to Help MS Patients When Added to Other Treatments
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    Sept. 13, 2010 -- Adding the asthma drug albuterol to a treatment for multiple sclerosis (MS) improved walking ability and delayed the time to first relapse among patients in a newly published study.

    Patients starting daily injections of the MS drug glatiramer acetate -- known by the brand name Copaxone -- showed improvement over the course of a year when oral albuterol was added to the treatment regimen.

    Those treated with Copaxone and placebo showed slight declines in function after a year of treatment, study researcher Samia J. Khoury, MD, of Harvard Medical School tells WebMD.

    The study was small, but Khoury says the findings indicate the inexpensive drug may be a useful addition to early MS treatment.

    "I do give albuterol to my patients early in treatment if they don't have contraindications," she says. "It is cheap and generally well tolerated and patients take just one pill a day."

    Albuterol for MS

    The inhaled form of albuterol is widely prescribed to patients with asthma, COPD, and other pulmonary diseases to open constricted airways.

    Khoury and colleagues at Harvard's Brigham and Women's Hospital first considered using albuterol as an additional early treatment for multiple sclerosis almost a decade ago.

    That was when the researchers first reported that the asthma drug inhibited production of specific inflammation-causing messenger proteins linked to MS, known as interleukin-12 (IL-12).

    High levels of IL-12 have been reported in patients with secondary progressive MS, which is an advanced form of the disease characterized by progressive symptoms and few or no relapses.

    Disease-modifying drugs like Copaxone, interferon-beta 1a and 1b, and Tysabri appear to slow the progression from early disease to secondary progressive MS. It is now recommended that patients consider starting these treatments as early as possible following diagnosis.

    In the newly reported study, Khoury and colleagues randomly assigned 44 patients with relapsing-remitting MS who had not previously received treatment affecting the immune system to receive daily injections of Copaxone with oral albuterol or a placebo pill for up to two years.

    Neurological testing was performed at the beginning of the study and again at three, six, 12, 18, and 24 months. Blood samples were collected four times over the first year. Brain imaging to look for the lesions associated with MS was also performed at enrollment and at 12 and 24 months.

    Today on WebMD

    nerve damage
    Learn how this disease affects the nervous system.
    woman applying lotion
    Ideas on how to boost your mood and self-esteem.
    woman pondering
    Get personalized treatment options.
    man with hand over eye
    Be on the lookout for these symptoms.
    brain scan
    worried woman
    neural fiber
    white blood cells
    sunlight in hands
    marijuana plant
    muscle spasm